For cancer risk reduction trials in the breast for e.g., there are certain conditions in which risk of cancer is so high, as in BRCA1 mutation carriers who have 30%-70% lifetime risk of developing breast cancer that the standard of care is to offer risk reduction mastectomy [61]. This evidence concerns the gene BRCA1 and breast cancer.